Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 190.00

From 52W high−31.37%

Volume100950.00

Market capHKD 15.17B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 190.00

From 52W high

−31.37%

Volume

100950.00

Market cap

HKD 15.17B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

48.2

MomentumView details →

1D Return

+1.42%

YTD Return

+41.80%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+1.42%

YTD Return

+41.80%

1Y Return

—

RSI (14)

48.2

vs 50D SMA

−0.17%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Haixi New Drug (02637.HK) reported interim results for the six months ended June 2026, with revenue of RMB 312 million, up 3.9% year-on-year, and net profit attributable to shareholders of RMB 81.05 million, down 24.8%.21d ago

Haixi New Drug's candidate drug molecule HX9428 was granted Fast Track designation by the U.S. FDA for the treatment of neovascular age-related macular degeneration.34d ago

Similar companies

Neurocrine Biosciences, Inc.NBIX 步长制药603858.SH 华润江中600750.SH 海正药业600267.SH 华润双鹤600062.SH 九洲药业603456.SH Find similar companies →

Latest newsMore news →

Haixi New Drug (02637.HK) reported interim results for the six months ended June 2026, with revenue of RMB 312 million, up 3.9% year-on-year, and net profit attributable to shareholders of RMB 81.05 million, down 24.8%.21d ago Haixi New Drug's candidate drug molecule HX9428 was granted Fast Track designation by the U.S. FDA for the treatment of neovascular age-related macular degeneration.34d ago Haixi New Drug (02637) announced that it has officially initiated a second Phase II clinical study of HX9428 for treating nAMD in China, with the registration information disclosed on the NMPA CDE platform.47d ago